Navigation Links
Vermillion Announces First Quarter 2008 Financial Results and Business Progress
Date:5/15/2008

- Company Focused on Commercialization in 2008 -

FREMONT, Calif., May 15 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, today announced financial results for the first quarter ended March 31, 2008, and provided an update on recent corporate and clinical developments.

"During the first quarter of 2008, we demonstrated significant clinical and commercialization progress in each of our diagnostic programs. These programs target significant unmet clinical needs and present attractive revenue opportunities. It is an exciting time as we explore strategic business development options that are synergistic with our Quest Diagnostics' alliance," said Gail Page, President and CEO of Vermillion.

The Company plans to finalize its clinical study examining the Ovarian Tumor Triage Test, now named OVA1(TM), and submit OVA1 to the U.S. Food and Drug Administration (FDA) in the second quarter of this year. Additionally, Vermillion is working on clinical studies and building market awareness of the PAD blood test, now named VASCLIR(TM) the PAD test. Throughout the remainder of 2008, the Company will focus on commercialization efforts.

First Quarter 2008 Financial Results

As a result of the November 13, 2006 sale of its former instrument business to Bio-Rad Laboratories, the Company does not anticipate significant revenue until its diagnostic tests are commercialized. During the first quarter of 2008, products revenue of $5,000 was generated from the sale of thrombotic thrombocytopenic purpura ("TTP") test component materials to The Ohio State University Research Foundation ("OSU").

Total operating expenses decreased in the first quarter of 2008 to $4.6 million,
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
11. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) clinical ... segments, including the molecular diagnostics industry. BCC Research reveals in its new report that ... lower test costs, and a growing need for better diagnostics as part of a ...
(Date:7/1/2015)... 1, 2015  Axovant Sciences Ltd. (NYSE:  AXON), ... treatment of dementia, today announced that the company ... at 5:45 p.m. EDT following its presentation of ... Conference 2015 (AAIC). The event ... Dr. Lawrence Friedhoff , Chief Development Officer, ...
(Date:7/1/2015)... , July 1, 2015 InferMed ... technology will ... evidence-based clinical s olutions suite   ... and medical information products and services, announced today the acquisition ... decision support (CDS) technology company. InferMed,s Arezzo technology ...
(Date:7/1/2015)... 2015  UCB, a multinational biopharmaceutical company, and ... in designing, transforming, and running intelligent business operations, ... of their close collaboration in driving transformation that ... services (GBS) finance organization. The Aecus ... work together effectively to embrace the innovative promise ...
Breaking Biology Technology:NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5
... All amounts are in U.S. dollars, QUEBEC ... AEZS; TSX: AEZ;), a global biopharmaceutical company focused ... completed the sale,of its Quebec City property for ... AEterna Zentaris also entered into a long-term lease ...
... 27 /Xinhua-PRNewswire-FirstCall/ -- China Clean,Energy Inc. (OTC ... a leading producer of environmentally-friendly specialty,chemical products ... Republic of,China, today announced that it continues ... its specialty chemical products and that it,continues ...
... New spray-on films developed by UC San Diego chemists ... quickly reveal trace amounts of nitrogen-based explosives. , Contaminated ... blue under ultraviolet light. One of the films can ... that could provide evidence to help solve a crime, ...
Cached Biology Technology:AEterna Zentaris Sells Quebec City Building for $7.1 million 2China Clean Energy Updates Business Outlook 2China Clean Energy Updates Business Outlook 3Glowing films developed by UC San Diego chemists reveal traces of explosives 2
(Date:6/17/2015)... SAN JOSE, Calif. , June 17, 2015 ... leader in human interface solutions, today announced that ... has adopted the Synaptics ® ClearPad ® ... family of display driver integrated circuits (DDICs) for ... Note Pro. By leveraging ClearPad for full in-cell ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint Cards ... communicated that it will amount to at least 340 MSEK ... to the rapid increase in market growth and orders received ... communicated guidance that revenue for 2015 will exceed 1,500 MSEK ... to approximately 2,200 MSEK. Due to receipt of ...
(Date:6/11/2015)... , June 11, 2015 Daon, ... announced today that its IdentityX Mobile Authentication Platform ... IDentity Online) Alliance is an industry consortium launched ... standards for simpler, stronger authentication.  In order to ... pass a rigorous series of tests that measure ...
Breaking Biology News(10 mins):Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... chemicals may one day be synthesised using biotechnology, following ... provide soldier beetles with their potent predator defence system., ... published details of the gene identification breakthrough and potential ... ., "For the first time, our team has been ...
... A study conducted by scientists at the Royal Botanic Gardens, ... climate change alone could lead to the extinction of wild ... of this century. Wild Arabica is considered important ... considerable genetic diversity. The Arabicas grown in the world,s coffee ...
... causes lung-damaging inflammation in cystic fibrosis (CF), and that ... finding offers a potential new drug target for treating ... illness and death for people with CF. "Developing ... big step forward," says Dr. Stuart Turvey, who led ...
Cached Biology News:Gene find turns soldier beetle defence into biotech opportunity 2New study suggests that Arabica coffee could be extinct in the wild within 70 years 2New study suggests that Arabica coffee could be extinct in the wild within 70 years 3New study suggests that Arabica coffee could be extinct in the wild within 70 years 4New study suggests that Arabica coffee could be extinct in the wild within 70 years 5New drug target found for cystic fibrosis lung disease 2
... This antibody is specific for human cardiac troponin ... the Ca-binding signals responsible for contraction of cardiac ... troponin complex in human cells. It also cross-reacts ... Antigen: Highly purified human ...
... N-(2-Naphthoyl)-Val-phenylalaninal 2-Naphthoyl-VF-CHO White ... INERT GAS. A cell-permeable, reversible inhibitor of ... x-40 (ED 50 = 2.6 ... = 2.7 μM) in HEK293 cells ...
cystatin A (N-18)...
...
Biology Products: